Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inspire Medical Systems (INSP) Total Liabilities (2017 - 2025)

Historic Total Liabilities for Inspire Medical Systems (INSP) over the last 9 years, with Q4 2025 value amounting to $126.2 million.

  • Inspire Medical Systems' Total Liabilities rose 629.3% to $126.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was $126.2 million, marking a year-over-year increase of 629.3%. This contributed to the annual value of $126.2 million for FY2025, which is 629.3% up from last year.
  • As of Q4 2025, Inspire Medical Systems' Total Liabilities stood at $126.2 million, which was up 629.3% from $141.3 million recorded in Q3 2025.
  • In the past 5 years, Inspire Medical Systems' Total Liabilities ranged from a high of $141.3 million in Q3 2025 and a low of $50.3 million during Q1 2021
  • In the last 5 years, Inspire Medical Systems' Total Liabilities had a median value of $89.6 million in 2023 and averaged $86.6 million.
  • As far as peak fluctuations go, Inspire Medical Systems' Total Liabilities tumbled by 217.6% in 2022, and later soared by 6628.69% in 2023.
  • Quarter analysis of 5 years shows Inspire Medical Systems' Total Liabilities stood at $66.0 million in 2021, then grew by 4.29% to $68.9 million in 2022, then skyrocketed by 51.44% to $104.3 million in 2023, then rose by 13.8% to $118.7 million in 2024, then grew by 6.29% to $126.2 million in 2025.
  • Its last three reported values are $126.2 million in Q4 2025, $141.3 million for Q3 2025, and $124.4 million during Q2 2025.